Climb Bio Inc
CLYM4.729USD
-0.171-3.49%
Market hours （ET）Quotes delayed by 15 min
322.44MMarket Cap
LossP/E TTM
More Details of Climb Bio Inc Company
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
Climb Bio Inc Info
Ticker SymbolCLYM
Company nameClimb Bio Inc
IPO dateAug 10, 2021
CEOBrennan (Aoife M)
Number of employees17
Security typeOrdinary Share
Fiscal year-endAug 10
Address20 William Street
CityWELLESLEY HILLS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02481
Phone18668572596
Websitehttps://climbbio.com/
Ticker SymbolCLYM
IPO dateAug 10, 2021
CEOBrennan (Aoife M)
Company Executives of Climb Bio Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Director
Director
--
--
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
26.26%
Pontifax Venture Capital
7.64%
The Vanguard Group, Inc.
1.93%
Affinity Asset Advisors LLC
1.91%
Kynam Capital Management LP
1.51%
Other
60.76%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
26.26%
Pontifax Venture Capital
7.64%
The Vanguard Group, Inc.
1.93%
Affinity Asset Advisors LLC
1.91%
Kynam Capital Management LP
1.51%
Other
60.76%
Shareholder Types
Shareholders
Proportion
Venture Capital
33.94%
Hedge Fund
9.63%
Investment Advisor
8.07%
Investment Advisor/Hedge Fund
1.20%
Individual Investor
0.81%
Research Firm
0.80%
Other
45.56%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
180
50.12M
94.21%
+7.08K
2025Q3
182
50.11M
95.00%
-5.30M
2025Q2
174
55.41M
95.70%
-2.05M
2025Q1
161
57.46M
90.60%
-8.97M
2024Q4
149
56.10M
86.82%
+979.54K
2024Q3
120
56.83M
81.50%
+4.66M
2024Q2
84
51.93M
31.41%
+31.40M
2024Q1
82
18.86M
80.37%
-3.42M
2023Q4
86
18.86M
80.98%
+125.11K
2023Q3
87
18.73M
82.50%
-1.84K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
31.42M
46.37%
--
--
Jun 30, 2025
Pontifax Venture Capital
5.21M
7.68%
+5.21M
--
Mar 31, 2025
The Vanguard Group, Inc.
1.33M
1.96%
-171.31K
-11.40%
Jun 30, 2025
Affinity Asset Advisors LLC
1.50M
2.21%
--
--
Jun 30, 2025
Kynam Capital Management LP
1.03M
1.52%
-18.66K
-1.78%
Jun 30, 2025
Tang Capital Management, LLC
1.00M
1.48%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
829.63K
1.22%
-1.27M
-60.45%
Jun 30, 2025
Peapod Lane Capital LLC
555.67K
0.82%
+1.85K
+0.33%
Jun 30, 2025
Cantor Fitzgerald, L.P
2.50M
3.69%
+503.12K
+25.16%
Jun 30, 2025
Renaissance Technologies LLC
495.50K
0.73%
-18.90K
-3.67%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 Growth ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Neuroscience and Healthcare ETF
0%
iShares Russell 2000 Value ETF
0%
View more
ProShares Ultra Nasdaq Biotechnology
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
Invesco Nasdaq Biotechnology ETF
Proportion0.01%
iShares Micro-Cap ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Neuroscience and Healthcare ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Climb Bio Inc?
The top five shareholders of Climb Bio Inc are:
RA Capital Management, LP holds 31.42M shares, accounting for 46.37% of the total shares.
Pontifax Venture Capital holds 5.21M shares, accounting for 7.68% of the total shares.
The Vanguard Group, Inc. holds 1.33M shares, accounting for 1.96% of the total shares.
Affinity Asset Advisors LLC holds 1.50M shares, accounting for 2.21% of the total shares.
Kynam Capital Management LP holds 1.03M shares, accounting for 1.52% of the total shares.
RA Capital Management, LP holds 31.42M shares, accounting for 46.37% of the total shares.
Pontifax Venture Capital holds 5.21M shares, accounting for 7.68% of the total shares.
The Vanguard Group, Inc. holds 1.33M shares, accounting for 1.96% of the total shares.
Affinity Asset Advisors LLC holds 1.50M shares, accounting for 2.21% of the total shares.
Kynam Capital Management LP holds 1.03M shares, accounting for 1.52% of the total shares.
What are the top three shareholder types of Climb Bio Inc?
The top three shareholder types of Climb Bio Inc are:
RA Capital Management, LP
Pontifax Venture Capital
The Vanguard Group, Inc.
RA Capital Management, LP
Pontifax Venture Capital
The Vanguard Group, Inc.
How many institutions hold shares of Climb Bio Inc (CLYM)?
As of 2025Q4, 180 institutions hold shares of Climb Bio Inc, with a combined market value of approximately 50.12M, accounting for 94.21% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.80%.
What is the biggest source of revenue for Climb Bio Inc?
In --, the -- business generated the highest revenue for Climb Bio Inc, amounting to -- and accounting for --% of total revenue.
